Today we enrolled our first subject in #ELEVATE HFpEF @ISHVnews! The study is exploring whether physiological pacing @ a personalized #myPACE lower rate improves outcomes in patients with HFpEF already on GDMT. We are thrilled to get started! @Medtronic

Great perspectives and insight on an important aspect of research @coconnormd @GarimaVSharmaMD @InovaCVfellows @ShashankSinhaMD @mpsotka @SumeetMitter

A new multicenter evaluation of 1538 patients with obstructive #HCM treated with #mavacamten Goal: provide real-world safety outcomes (recall mavacamten is very effective so we are not covering that) - Exposure (median): 13.4 months - Median dose 5 mg - AF incidence 13% - Of

We wrap up another Fall 2025 HFC Think Tank Meeting session with incredible discussions focused on site-based research Thanks to all those who attended and contributed to shaping the future of the field! #HFC #ThinkTankSeason

Happening now: Our Fall Think Tank is underway! 🌟 Leaders across the field are coming together to exchange ideas, challenge assumptions, and move the needle forward. Excited for the conversations and collaborations that will shape what’s next! #hfc #heartfailure #thinktank

Outcomes from the open label extension of #HELIOS-B - vutrisiran in ATTR-CM Patients originally randomized vutrisiran vs placebo 40% taf at baseline 10% total drop in taf Then open label vutrisiran #ESC2025 #cardioTwitter #MedIQESCCongress

Congrats to the authors, but 2 critical points: 1) There’s no role for PYP scan in setting of + monoclonal protein. 2) “Promptly diagnosing” does not mean 1-2 months from time of suspicion. When #AL #amyloidosis is in the differential, it’s a near-emergency — every day matters.

🔊 Registration is open! Join the #HFC Fall 2025 Think Tank – Sept 19 | 9–12:15 ET | Zoom 🎯 Focus: Site-Based Research ✅ Check out the agenda & speakers 👉 Register now: https://t.co/z7oUnoUNHS #heartfailure #Clinicaltrial #sitebasedresearch

Bringing @ISHVnews expertise to 3CT @ShashankSinhaMD-Serial Shock Assessment @cmrosner-Biomarkers/Patient Empowerment @coconnormd Moderator, AHF Personalize Post-Discharge @MaryLoobyPharmD, Sophia Pan poster - Glucose control/ Cardiac Surgery Panels: @SumeetMitter @mpsotka

#3CT in action! Infinitely proud of our #HFC members #clinicaltrial #heartfailure #heartfailurecollaboratory

High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy @matser89 @aldoporcari @TiniGiacomo @GSaturi @LauraDemichieli @albcipri6 #AHAJournals https://t.co/m4vcT1aFyM

When Cassidy practiced medicine he fought to vaccinate kids against Hep B. But in a desperate attempt to be re-elected to the senate next year, he chose to betray what he believes and supported an opponent of vaccines for HHS Sec. That will be his legacy.

Excited to have participated in this #Delphi study for the management of 🫀#sarcoidosis, just published in @JACCJournals. Covers lots of controversial topics in #sarcoid management. https://t.co/6S861gV2WP

With all the recent news about ATTR therapies, it is good to remember that it is not a benign disease. Outcomes have tremendously improved, but still lots of work to do. https://t.co/MWmxZmXyGF #cardiotwitter

Great to see this paper out in @JACCJournals Establishing the role of transthyretin (prealbumin) as a surrogate of treatment effect of transthyretin stabilizers in ATTR-CM, such as acoramidis in this particular paper https://t.co/B4DsSMqMLl #CardioTwitter

🔴 Early Increase in Serum TTR by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy @JACCJournals #Cardiology #CardioEd #Amyloidosis

Critical data - while bone scintigraphy has resulted in a massive improvement in our diagnostic abilities in transthyretin amyloidosis, it remains insufficient with significant limitations. In this report, patients with L58H variant had closed to 90% false negative PYP scans. In

Further analysis from ATTRIBUTE-CM utilizing different NTproBNP cut offs as a marker of disease severity, and evaluating outcomes/consistency of treatment effect #ACC25 #CardioTwitter ##MEDIQACC25

A further dive into the primary efficacy endpoint in ATTRibute-CM #ACC25 #CardioTwitter #MEDIQACC25

So glad to have another medication for our patients with TTR amyloid. @SumeetMitter